Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22144Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Drosos, A. A. | en |
| dc.contributor.author | Moutsopoulos, N. M. | en |
| dc.date.accessioned | 2015-11-24T19:22:06Z | - |
| dc.date.available | 2015-11-24T19:22:06Z | - |
| dc.identifier.issn | 0040-3660 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22144 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Cyclosporins/adverse effects/*therapeutic use | en |
| dc.subject | Double-Blind Method | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Salivary Glands/drug effects/secretion | en |
| dc.subject | Salivation/drug effects | en |
| dc.subject | Sjogren's Syndrome/drug therapy | en |
| dc.subject | Xerophthalmia/drug therapy | en |
| dc.subject | Xerostomia/drug therapy | en |
| dc.title | Effectiveness and safety of using cyclosporin A in the treatment of primary Sjogren's syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/3293257 | - |
| heal.language | ru | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1988 | - |
| heal.abstract | We used oral cyclosporine-A (CyA) (5 mg/kg/day) initially in a double blind study for 6 mos. 10 patients received CyA and 10 placebo. At the end of this study it was observed that CyA improved subjective xerostomia, while subjective xerophthalmia, parotid gland enlargement, Schirmer-I-test and parotid flow rate did not show any significant differences in the two study groups. 9 of 10 patients who had received CyA for 6 mos and 9 of 10 in the placebo group continued in an open trial (CyA at the same dose) for an additional 6 mos. At the end of the study the only efficacy of CyA observed was improvement of subjective xerostomia. The side-effects observed were hypertrichosis (14 persons), mild hypertension (4), infections (5) and 3 dropped out because of nausea, tremor, paresthesias and infections. In conclusion, small doses of CyA for 12 mos are rather ineffective for Sjogren's syndrome. | en |
| heal.journalName | Ter Arkh | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
